Barclays Rates Sotera Health (SHC) buy, $19 Price Target
Barclays maintains its buy rating on Sotera Health with a $19 price target, a 9.32% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Barclays rated Sotera Health Company ($SHC) "buy" with a $19 price target on June 24, 2026.
Since the rating, $SHC is up 6.3% after 1 week, up 4.0% after 1 month and up 7.2% to date (from the $16.69 close on Jun 24, 2026).
SHC
Sotera Health Company
Key Points
- Barclays reiterated its buy rating on Sotera Health Company (SHC) with a price target of $19 on June 24, 2026.
- Barclays's $19 price target implies 9.32% upside from Sotera Health Company's ($SHC) current $17.38 share price.
- Shares of Sotera Health traded near $17.14 on Friday, boasting a market cap of $4.88 billion and a P/E ratio of 41.7.
- Insiders, including CEO Alton Shader, have been actively buying shares, while analysts maintain a positive outlook.
Get $SHC trade alerts by text
We text you when insiders, Congress or big funds trade $SHC. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Sotera Health Company alert may contain errors. Disclosures
On June 24, 2026, Barclays reiterated its buy rating on Sotera Health Company (NasdaqGS: SHC), setting a price target of $19. Analyst Luke Sergott maintained the positive outlook, emphasizing the company's potential in the healthcare sector.
Barclays vs. the S&P 500
Hypothetical returns from Barclays's disclosed trades, not real profit or advice. How we model this.
Sotera Health Company Stock Down 7.2%
Shares of NasdaqGS:SHC traded near $17.14 on Friday. Sotera Health Company has a market cap of approximately $4.88 billion. The stock's P/E ratio stands at 41.7, with a forward P/E of 16.08, indicating investor confidence in future earnings growth. The company's beta is 1.797, suggesting higher volatility compared to the market. Over the past year, the stock ranged from a low of $10.93 to a high of $19.85. Its 50-day moving average is $15.75, while the 200-day moving average is $16.25. Financial health is supported by a current ratio of 2.82 and a quick ratio of 2.361, though the debt-to-equity ratio is relatively high at 364.72.
$SHC price target
Sotera Health Company daily closes and this analyst's $19 target. Not advice.
Recent Earnings
In its recent earnings report, Sotera Health posted revenue of about $1.19 billion, reflecting a 10% growth from the previous year. The company's earnings per share (EPS) was $0.41, with a net margin of 9.91%. Return on equity (ROE) stood at 22.73%, indicating strong profitability. The next earnings announcement is expected on May 5, 2026.
Insider Buying and Selling at Sotera Health Company
There has been notable insider buying activity at Sotera Health. On May 26, 2026, CEO Alton Shader acquired 681,390 shares in multiple transactions. Additionally, on May 22, insiders James Neary, Vincent Petrella, and David Wheadon each purchased 14,970 shares. These purchases were not part of a pre-planned trading program.
Analysts Set New Price Targets
On June 24, 2026, Barclays maintained its buy rating on Sotera Health with a $19 price target. Earlier this month, on June 5, 2026, Goldman Sachs initiated coverage with a buy rating and a $20 target. Piper Sandler reiterated its buy rating with a $22 target on May 6, 2026. The consensus among analysts is a buy rating, with a mean price target of $20.22 based on nine opinions.
About Sotera Health Company
Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry. It operates through three segments: Sterigenics, Nordion, and Nelson Labs, serving markets in the United States, Canada, Europe, and internationally. The company is headquartered in Broadview Heights, Ohio, and led by CEO Alton E. Shader. Founded in 2015, Sotera Health employs around 3,000 people.
Bottom Line
Barclays' reaffirmation of its buy rating underscores confidence in Sotera Health's growth potential and market position. With a strong market presence and recent insider buying, the company remains a point of interest for investors. As always, remember that analyst ratings reflect past data and may not indicate future performance.
Related Filing Alerts
Source: Barclays's rating change on $SHC (Jun 24, 2026). Written by software, not financial advice. How we make alerts